Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3632-3638

  Trail, Pamela A ^a   Willner, David ^a   Blanchi, Albert B ^a   Henderson, Arris J ^a   Trailsmith, Mark D ^a   Girit, Emel ^a   Lasch, Shirley ^a   Hellström, Ingegerd ^a,b   Hellström, Karl Erik ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BR 96; DOXORUBICIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; PACLITAXEL; RATS; RATS, NUDE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032760133     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hellström, I., Hellström, K. E., Siegall, C. B., and Trail, P. A. Immunoconjugates and immunotoxins for therapy of carcinomas. In: J. T. August, M. W. Anders, F. Murad, and J. T. Coyle (eds.), Advances in Pharmacology, Vol. 33, 1st ed., pp. 349-388. San Diego: Academic Press, 1995.
2. Ward, R. L., Hawkins, N. J., and Smith, G. M. Unconjugated antibodies for cancer therapy: lessons from the clinic. Cancer Treat. Rev., 23: 305-319, 1997.
3. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release, 53: 49-67, 1998.
4. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D. P. B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1268, 1993.
5. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J. A., Capdeville, R., Diehl, V., and Reyes, F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92: 1927-1932, 1998.
6. Mclaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Willimas, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
7. Reithmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H. Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
8. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S. J., Casazza, A. M., Firestone, R. A., Hellström, I., and Hellström, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
9. Willner, D., Trail, P. A., Hofstead, S. J., King, H. D., Lasch, S. J., Braslawsky, G. R., Greenfield, R. S., Kaneko, T., and Firestone, R. A. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem., 4: 521-527, 1993.
10. Sjogren, H. O., Isaksson, M., Willner, D., Hellström, I., Hellström, K. E., and Trail, P. A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res., 57: 4530-4536, 1997.
11. Saleh, M. N., Lobuglio, A. F., and Trail, P. A. Immunoconjugate therapy of solid tumors: studies with BR96-doxorubicin. In: M. Grossbard (ed.), Monoclonal Antibody-based Therapy of Cancer, pp. 397-416. New York: Marcel Dekker, 1998.
12. Amadori, D., Frassineti, G. L., Zoli, W., Milandri, C., Serra, P., Tienghi, A., Ravaioloi, A., Gentile, A., and Salzano, E. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Oncology, 4 (Suppl. 3): 30-33, 1997.
13. Gianni, L., and Capri, G. Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Semin. Oncol., 24 (1 Suppl. 3): S1-S3, 1997.
14. Dombernowsky, P., Boesgaard, M., Andersen, E., and Jensen, B. V. Doxorubicin plus paclitaxel in advanced breast cancer. Semin. Oncol., 24 (5 Suppl. 17): S17-S18, 1997.
15. Hancock M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
16. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W., Jr., Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
17. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized Anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
18. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, M. M., Tripathy, D., Baly, D., Baighman, S. A., Twaddell, T., Glaspy, J. A., and Slalom, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2663, 1998.
19. +/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 98a, 1998.
20. 1/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
21. Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
22. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
23. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.